The FDA on Dec. 14 approved a...

 ...two-hour infusion time for Roche's blockbuster multiple sclerosis drug Ocrevus. The news comes as Novartis launches its MS challenger, Kesimpta, which is self-administered. For the treatment of multiple sclerosis, Ocrevus is covered under the pharmacy benefit for 39% of covered lives, the medical benefit for 26% of covered lives, and both the medical and pharmacy benefit for 24% of covered lives. In the pharmacy benefit, Ocrevus holds preferred status for 6% of covered lives, growing to 17% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 12/17/20